CCL2 and Hepatic fibrosis: The present study demonstrates that in vivo administration of Mat affords protection from liver injury and development of liver fibrosis in CCl4-induced liver injury model, and such beneficial effects could be contributed, at least in part, to the prevention by Mat on the hepatic infiltration of the inflammatory Gr1hi monocyte subset in injured livers, which is most possibly through its inhibition of both MCP-1 production and activity.